Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity

Area of Science:

• Parasitology
• Infectious Diseases
• Drug Discovery

Background:

• Toxoplasma gondii is a widespread apicomplexan parasite infecting humans and animals.
• Current treatments like pyrimethamine and sulfadiazine have host toxicity and do not eliminate chronic, chemoresistant cysts.
• No approved treatments exist for pregnant women, and chronic infection eradication remains a challenge.

Purpose of the Study:

• To identify clinically available drugs with potential for treating toxoplasmosis.
• To explore less-toxic therapeutic options for acute and chronic Toxoplasma gondii infections.
• To find treatments capable of eradicating persistent, intracellular cysts.

Main Methods:

• Evaluation of clinically available drugs with demonstrated efficacy in disease models.
• Focus on drugs lacking extensive clinical case reports for toxoplasmosis.
• Assessment of potential for both acute disease amelioration and chronic cyst clearance.

Main Results:

• Identification of promising drug candidates for further investigation.
• Potential for developing treatments with improved host safety profiles.
• Exploration of novel strategies against chemoresistant intracellular cysts.

Conclusions:

• There is a critical need for new, safer, and more effective toxoplasmosis treatments.
• Repurposing existing drugs offers a viable strategy for developing novel therapies.
• Further research is warranted to validate these candidates for clinical use and cyst eradication.